On March 8, 2024, Novo Nordisk announced that the FDA approved Wegovy® to reduce cardiovascular risks in overweight or obese adults with cardiovascular disease, demonstrating a 20% risk reduction in major adverse cardiovascular events compared to placebo. This approval marks a significant milestone for managing obesity-related health issues.